Wynzora is a drug owned by Mc2 Therapeutics Ltd. It is protected by 3 US drug patents filed from 2020 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 18, 2039. Details of Wynzora's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11638711 | NULL |
Mar, 2039
(13 years from now) | Active |
| US11696919 | Topical composition |
Mar, 2039
(13 years from now) | Active |
| US10265265 | Topical composition |
Sep, 2027
(2 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Wynzora's patents.
Latest Legal Activities on Wynzora's Patents
Given below is the list of recent legal activities going on the following patents of Wynzora.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent eCofC Notification | 19 Mar, 2024 | US11696919 |
| Mail Patent eCofC Notification | 19 Mar, 2024 | US11638711 |
| Mail Patent eCofC Notification | 19 Mar, 2024 | US11696919 |
| Patent eCofC Notification | 19 Mar, 2024 | US11638711 |
| Email Notification Critical | 19 Mar, 2024 | US11696919 |
| Recordation of Patent eCertificate of Correction | 19 Mar, 2024 | US11696919 |
| Email Notification Critical | 19 Mar, 2024 | US11638711 |
| Recordation of Patent eCertificate of Correction | 19 Mar, 2024 | US11638711 |
| Mail Certificate of Correction Memo | 28 Feb, 2024 | US11696919 |
| Mail Certificate of Correction Memo | 28 Feb, 2024 | US11638711 |
FDA has granted several exclusivities to Wynzora. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Wynzora, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Wynzora.
Exclusivity Information
Wynzora holds 1 exclusivities. All of its exclusivities have expired in 2023. Details of Wynzora's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jul 20, 2023 |
US patents provide insights into the exclusivity only within the United States, but Wynzora is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Wynzora's family patents as well as insights into ongoing legal events on those patents.
Wynzora's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Wynzora's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 18, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Wynzora Generic API suppliers:
Betamethasone Dipropionate; Calcipotriene is the generic name for the brand Wynzora. 5 different companies have already filed for the generic of Wynzora, with Padagis Israel having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Wynzora's generic
Alternative Brands for Wynzora
Wynzora which is used for treating schizophrenia, bipolar disorder, and major depressive disorder., has several other brand drugs using the same active ingredient (Betamethasone Dipropionate; Calcipotriene). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Betamethasone Dipropionate; Calcipotriene, Wynzora's active ingredient. Check the complete list of approved generic manufacturers for Wynzora
About Wynzora
Wynzora is a drug owned by Mc2 Therapeutics Ltd. It is used for treating schizophrenia, bipolar disorder, and major depressive disorder. Wynzora uses Betamethasone Dipropionate; Calcipotriene as an active ingredient. Wynzora was launched by Mc2 in 2020.
Approval Date:
Wynzora was approved by FDA for market use on 20 July, 2020.
Active Ingredient:
Wynzora uses Betamethasone Dipropionate; Calcipotriene as the active ingredient. Check out other Drugs and Companies using Betamethasone Dipropionate; Calcipotriene ingredient
Treatment:
Wynzora is used for treating schizophrenia, bipolar disorder, and major depressive disorder.
Dosage:
Wynzora is available in cream form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.064%;0.005% | CREAM | Prescription | TOPICAL |